Literature DB >> 17486495

Genotypic correlation between six common beta-thalassemia mutations and the XmnI polymorphism in the Moroccan population.

Imane Agouti1, Catherine Badens, Ahmed Abouyoub, Mohamed Khattab, Fouad Sayah, Amina Barakat, Mohcine Bennani.   

Abstract

beta-Thalassemia (thal) is the most common recessive inherited disorder in Mediterranean populations. It is estimated that the frequency of this disease in the Moroccan population is between 1.5 and 3.0%. Severe forms of homozygous thalassemia cases require expensive and technically demanding curative (bone marrow transplantation) or palliative (chronic transfusion/chelation) therapies. The -158 (C-->T) polymorphism of the (G)gamma-globin gene (XmnI polymorphism) is known to ameliorate the severity of the disease because of it strong association with an increased production of fetal hemoglobin (Hb F). Among the many known mutations in Morocco, six are common [codon 39 (C-->T), frameshift codon (FSC) 8 (-AA), IVS-II-745 (CG), FSC 6 (-A), -29 (A-->G) and IVS-I-1 (G-->A)]. In this study, we have investigated, in 82 Moroccan beta-thalassemic chromosomes, the correlation between the six common mutations and the XmnI polymorphism using the Fisher exact test. The XmnI polymorphism was divided into two categories, (XmnI [+] and XmnI [-]) and the six common Moroccan mutations into two groups (group I with FSC 8 and group II without FSC 8). Correlation was carried out between the XmnI [+] category and the six common mutations individually that showed that 68% of chromosomes in the XmnI [+] category had the FSC 8 (-AA) mutation. The results reported here show that there is a positive correlation between the XmnI polymorphism and FSC 8 mutation in linkage with haplotype IV [- + - + + - +] (p <10(-5)). In conclusion, molecular determination of genetic markers in early childhood will help to identify candidates for pharmacological Hb F switching by hydroxyurea (HU). In the Moroccan population, a good response to HU treatment should be suspected in cases with the -158 (C-->T) polymorphism in linkage with haplotype IV and internal beta-globin gene framework 3.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17486495     DOI: 10.1080/03630260701285050

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  6 in total

1.  Epidemiological profile of common haemoglobinopathies in Arab countries.

Authors:  Hanan A Hamamy; Nasir A S Al-Allawi
Journal:  J Community Genet       Date:  2012-12-08

2.  Sickle Cell Disease in Jordan: The Experience of a Major Referral Center.

Authors:  Raida I Oudat; Heba S Abualruz; Nazih Kh Abu Al-Shiek; Eman A Al-Mashaqba; Rawan A Al-Hiari; Hala A Alsoukhni; Ma'mon A Abu Hammad
Journal:  Med Arch       Date:  2021-02

3.  Prevalence of Xmnl Gγ polymorphism in Egyptian patients with β-thalassemia major.

Authors:  Azza A G Tantawy; Nevine G Andrawes; Amany Ismaeil; Solaf A Kamel; Wessam Emam
Journal:  Ann Saudi Med       Date:  2012 Sep-Oct       Impact factor: 1.526

4.  Molecular heterogeneity of β-thalassemia variants in the Eastern region of Morocco.

Authors:  Ihab Belmokhtar; Saida Lhousni; Mounia Elidrissi Errahhali; Ayad Ghanam; Manal Elidrissi Errahhali; Zaina Sidqi; Meryem Ouarzane; Majida Charif; Mohammed Bellaoui; Redouane Boulouiz; Noufissa Benajiba
Journal:  Mol Genet Genomic Med       Date:  2022-05-26       Impact factor: 2.473

5.  The Effect of Xmn -1 Polymorphism and Coinheritance of Alpha Mutations on Age at First Blood Transfusion in Iranian Patients with Homozygote IVSI-5 Mutation.

Authors:  Mozhgan Hashemieh; Zahra Al Sadat Saadatmandi; Azita Azarkeivan; Hossein Najmabadi
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2022-01-01

6.  beta-Thalassaemia Major in a Spanish Patient due to a Compound Heterozygosity for CD39 C --> T/-28 A --> C.

Authors:  Soledad Gamarra; Guillermo Garcia-Effron; Carmen Monteserin; Isabel Lopez-Villar; Florinda Gilsanz; Joaquín Martinez-Lopez
Journal:  Adv Hematol       Date:  2009-07-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.